

**Drug Utilization Review (DUR) Meeting Minutes
September 4, 2019**

Members Present: Michael Quast, Gabriela Balf, Tanya Schmidt, Andrea Honeyman, Peter Woodrow, Laura Schield, Jennifer Iverson

Members Absent: Michael Booth, Russ Sobotta, Katie Kram, LeNeika Roehrich

Medicaid Pharmacy Department: Brendan Joyce, Alexi Murphy

Old Business

T. Schmidt served as interim chair and the meeting to order at 1:05 p.m. Chair T. Schmidt asked for a motion to approve the minutes of the June meeting. G. Balf moved that the minutes be approved, and A. Honeyman seconded the motion. The chair called for a voice vote to approve the minutes. The motion passed with no audible dissent.

Review Top 15 Therapeutic Categories/Top 25 Drugs

B. Joyce presented the quarterly review of the top 15 therapeutic classes by total cost of claims, top 25 drugs based on number of claims, and top 25 drugs based on claims cost for the 2nd quarter of 2019.

PDL/PA Criteria Updates

A. Murphy shared with the Board all of changes made to the Preferred Drug List since the most recent version of the Preferred Drug List was posted. Notable changes included removing PA requirements for a number of pulmonary hypertension agents and NSAIDs, as well as adding numerous agents to recently DUR Board approved PA class criteria. When a new version of the PDL is published and posted to the website, all updates/changes made since the last version are called out at the top of the document itself.

Second Review of Short-Acting Opioid Analgesic Agents

A motion and second was made at the June meeting to place select short-acting opioid analgesic agents on prior authorization. The topic was brought up for a second review. There was no public comment. Chair T. Schmidt called for a voice vote and the motion passed with no audible dissent.

Second Review of Agents for the Treatment of Thrombocytopenia

A motion and second was previously made to place agents for the treatment of thrombocytopenia on prior authorization. The topic was brought up for a second review. There was no public comment. Chair T. Schmidt called for a voice vote and the motion passed with no audible dissent.

Second Review of Agents for Treatment of Interstitial Cystitis

A motion and second was made at the June meeting to place agents for the treatment of interstitial cystitis on prior authorization. The topic was brought up for a second review. There was no public comment. Chair T. Schmidt called for a voice vote and the motion passed with no audible dissent.

Second Review of Agents for the Treatment of Narcolepsy

A motion and second was made at the June meeting to place agents for the treatment of narcolepsy on prior authorization. The topic was brought up for a second review. There was no public comment. Chair T. Schmidt called for a voice vote and the motion passed with no audible dissent.

Sanford Health Plan Update

Danny Weiss, representing Sanford Health Plan, spoke regarding ND Medicaid Expansion. In mid-year 2019, there were 19,226 average members per month with 78% of members utilizing benefits. The generic fill rate was 86.1%. The cost of specialty medications during that time accounted for 29.2% of total costs. The presentation focused on breakdowns of costs associated with specialty vs. non-specialty medications.

New Business

Review of Antifungal Agents for Aspergillus and Candidiasis Infections

A. Murphy presented a review of short-acting opioid agents to the Board. A motion was made by P. Woodrow to create PA criteria for the use of these agents and manage these medications through prior authorization. The motion was seconded by M. Quast. This topic will be reviewed at the next meeting.

Utilization Review of Rescue Inhalers and ADHD Products

T. DeRuiter presented data on the utilization of rescue inhalers and ADHD Products in the fee-for-service Medicaid population. The data indicated an overall reduction in rescue inhaler use per patient since 2015. Data also indicated that the utilization of Adderall as compared to Vyvanse has decreased drastically over the years with 2019 being the first year where Vyvanse is being used at a higher rate than Adderall. of therapeutic duplication with benzodiazepine and or sedative agents, drilled down to most commonly duplicated agents and regimen.

Retrospective Drug Utilization Review (RDUR) Criteria Recommendations

The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and are usually consistent with new indications, new drugs added, and new warnings. These proposed criteria will be added to the current set of criteria and will be used in future DUR cycles. T. Schmidt moved to approve the new criteria and G. Balf seconded the motion. The motion passed with no audible dissent.

Case Reviews

B. Joyce and A. Murphy presented cases for the DUR Board to review for any potential areas for improvement through targeted interventions, claims processing edits, or other intervention methods.

Adjournment and Upcoming Meeting Date

Chair T. Schmidt adjourned the meeting at 2:45 pm. The next DUR Board meeting will be held December 4, 2019 at 1:00 pm at the State Capitol building in the Brynhild -Haugland room.